CNVS — Cineverse Corp.

Cineverse Corp. Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: $12.7 million, a decrease of 3% year-over-year. Adjusted revenue, including a $1.1 million licensing deal for Toxic Avenger, would have been $13.4 million, reflecting a 5% increase.
• Gross Margin: Improved to 58%, up from 51% in the prior year, exceeding guidance of 45-50%.
• Net Loss: $5.5 million, compared to a loss of $1.2 million in the previous year.
• Adjusted EBITDA: Negative $3.7 million, down from a positive $500,000 year-over-year.
• Cash Position: $2.3 million in cash and cash equivalents, with $5.9 million available on a $12.5 million working capital facility.
• Content Library Valuation: Increased to $45 million, significantly above the book value of $3.2 million.

2. Strategic Updates and Business Highlights:

• Licensing and Distribution: Closed a $1.1 million licensing deal for Toxic Avenger, which is expected to perform well in ancillary markets, particularly VOD and licensing.
• Upcoming Releases: Two films, Silent Night, Deadly Night and Return to Silent Hill, are set to follow the successful release strategy of low-cost, fan-centric horror films.
• Matchpoint Technology: The technology sales pipeline is growing, with 20 new customers added recently, and ongoing evaluations by major studios.
• MicroCo Initiative: A joint venture focused on micro dramas is gaining traction, with significant interest from investors and the creative community.

3. Forward Guidance and Outlook:

• Management expects strong revenue and profitability growth in the latter half of the fiscal year, driven by investments in technology and marketing.
• Anticipated returns from the Toxic Avenger and upcoming films are expected to enhance financial performance.
• The company is optimistic about the potential of the MicroCo venture and its ability to capture a significant share of the micro drama market.

4. Bad News, Challenges, or Points of Concern:

• Box Office Performance: Toxic Avenger underperformed at the box office, though it is expected to be profitable through ancillary markets.
• Increased Losses: The net loss and negative adjusted EBITDA reflect higher SG&A expenses due to investments in growth initiatives.
• Advertising Market Pressures: The advertising environment remains mixed, with CPM rates under pressure due to increased inventory and macroeconomic concerns.
• Sales Cycle for Matchpoint: The sales cycle for Matchpoint technology is lengthy, with significant bureaucratic hurdles in large studios potentially delaying revenue recognition.

5. Notable Q&A Insights:

• Management acknowledged that the mixed-genre nature of Toxic Avenger may have contributed to its box office struggles, indicating a shift towards more straightforward genre films in the future.
• Regarding Matchpoint, management highlighted the strong interest from studios facing margin pressures, but noted that the transition to their technology could take time due to existing legacy systems.
• There is a focus on expanding partnerships and possibly pursuing M&A opportunities to enhance growth and market share in the technology space.

Overall, Cineverse Corp. is navigating a challenging environment with strategic investments aimed at long-term growth, despite facing short-term financial pressures and market uncertainties.